ILMN Illumina Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
20:59
May 29
May 29
Illumina long as narrative momentum.
Illumina rallied 22% purely on retail narrative because it was named as a stock on the Trump China trip. This speculative momentum trade can still work in the current market environment.
LOW
19:57
May 17
May 17
One highly upvoted comment (+7) advises “MU and ILMN. Calls for both.” ILMN (Illumina) is linked as a momentum trade alongside MU, likely on genomic/AI crossover narrative. Buy calls on ILMN, piggybacking on MU’s strength. Only one mention; no catalysts or volume discussed; low conviction.
MED
02:12
May 14
May 14
The author asks a rhetorical question about owning Illumina stock based on the CEO's Beijing trip, expressing curiosity rather than a directional view.
HIGH
21:42
May 13
May 13
Illumina benefits from China deal.
Illumina (ILMN) is a small genomics company on the list of CEOs traveling with Trump to China. It was banned from selling in China, but if Trump negotiates a deal to allow US chip exports, Illumina could re-enter the Chinese market. The stock hasn't priced this in, making it a short-term trade with asymmetric upside. I bought a small position.
MED
15:23
May 13
May 13
Illumina potential China re-entry trade
Illumina (ILMN) is a small position bet on Trump's China trip leading to a deal that allows the company to re-enter the Chinese market after being blacklisted. The stock has not rallied on this news, offering asymmetric upside.
MED
13:15
May 13
May 13
The Kobeissi Letter reports a list of CEOs joining Trump's China trip but only offers a vague bullish view on the summit's potential outcomes without explicit directional calls on any ticker.
HIGH
20:03
May 12
May 12
The tweet provides a detailed technical and cross-asset analysis highlighting overbought conditions, defensive rotation, and rising VIX that suggest a cautious or bearish outlook without explicitly stating the author's own directional trade.
22:34
May 01
May 01
Illumina has strong sustainable growth
Illumina has found sustainable growth momentum driven by clinical genomics, especially oncology, as genomic sequencing becomes standard of care; new innovations like TruePath support long-term opportunity.
HIGH
About ILMN Analyst Coverage
Buzzberg tracks ILMN (Illumina Inc.) across 6 sources. 5 bullish vs 0 bearish calls from 6 analysts. Sentiment: predominantly bullish (62%). 8 total trade ideas tracked.